HiringNot enough data
We need a relevant verified event before scoring this dimension.
O
Artificial Intelligence · San Francisco, United States
OpenAI
Current work outlook
OpenAI and Google Cloud announced a partnership that will make OpenAI frontier models and Codex agentic workflows available through Google Cloud's Model Garden and Marketplace. General availability is planned in the coming weeks, with an initial private preview for selected enterprise customers.
Updated October 21, 2026 · Evidence from public sources
Flags outlook69/ 100Positive
2 verified signals in this assessment
Why this score
Built from company events, not anonymous ratings.
The recent evidence is constructive, but the specific role and team still matter. The score weighs signal recency and source confidence. It is a decision aid—not a verdict on culture or a specific team.
StabilityNot enough data
We need a relevant verified event before scoring this dimension.
Financial healthNot enough data
We need a relevant verified event before scoring this dimension.
InnovationNot enough data
We need a relevant verified event before scoring this dimension.
Company timeline
What changed—and why it matters
Read events in order and look for repeated momentum or recurring risk.
Filter in all signals ↗OpenAI brings frontier models and Codex workflows to Google Cloud
OpenAI and Google Cloud announced a partnership that will make OpenAI frontier models and Codex agentic workflows available through Google Cloud's Model Garden and Marketplace. General availability is planned in the coming weeks, with an initial private preview for selected enterprise customers.
Employee impact
Read full analysis →The partnership broadens OpenAI's enterprise distribution and creates implementation work around cloud infrastructure, governance, security and developer tooling. For Google Cloud teams, it also increases the importance of multi-model platform expertise rather than work centered only on Gemini.
OpenAI acquires Orchestra Bio to expand AI-powered drug development
OpenAI acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug-development programs with AI agents. OpenAI plans to integrate Orchestra's team and technology with Rosalind, its models and tools for life-sciences research; financial terms were not disclosed.
Employee impact
Read full analysis →The acquisition signals continued investment in specialized life-sciences AI and may create opportunities at the intersection of software, biology and pharmaceutical operations. Orchestra employees should clarify integration, reporting lines and product continuity, while candidates should verify whether roles require deep domain expertise or regulated-industry experience.